Skip to main content Skip to section navigation Skip to footer
Kazia Therapeutics Corporate homepage
  • About Us
    • Company Overview
    • Management
    • Board of Directors
  • Pipeline
    • Pipeline Overview
    • Paxalisib
    • PD-L1 Protein Degrader
    • SETDB1 Inhibitor
    • EVT801
    • Clinical Trials
    • Posters & Publications
  • Technology
  • Media Center
    • Media Center Overview
    • News
    • Events
    • In The News
    • Video Gallery
    • ASX Announcements
  • Investors
    • Investors Overview
    • News & Events
    • Company Info
    • Financial Results
    • Stock Data
    • SEC Filings
    • Governance
    • ASX Delisting
  • Contact Us

ASX Announcements

Media Center

  • Media Center Overview
  • News
  • Events
  • In The News
  • Video Gallery
  • ASX Announcements
Apr 14, 2023
Kazia regains compliance with Nasdaq minimum bid requirement
Apr 12, 2023
Notification of cessation of securities - KZA
Apr 6, 2023
Change in substantial holding
Apr 4, 2023
Kazia presents new data at AACR Annual Meeting
Mar 21, 2023
Change of Director's Interest Notice
Mar 17, 2023
Change of Director's Interest Notice
Mar 8, 2023
Notification of cessation of securities - KZA
Mar 7, 2023
Change in substantial holding
Mar 7, 2023
Clinical Collaboration for Phase II clinical study
Mar 6, 2023
Notification regarding unquoted securities - KZA
rss_feed RSS
  • Previous Pagearrow_back
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • …
  • Page 19
  • Next Pagearrow_forward
©2026 Kazia Therapeutics. All Rights Reserved.
  • Privacy Policy
  • Disclaimer
  • Sitemap
  • Accessibility Statement